Vascular effects of estrogens: Arterial protection versus venous thrombotic risk

Trends in Endocrinology and Metabolism

Volumn 12, Issue 5, 2001, Pages 204-209

  Bracamonte, Margarita P ^a   Miller, Virginia M ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; LIGAND;

ARTERIOSCLEROSIS; ARTICLE; BLOOD CLOTTING; BLOOD FLOW; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; FEMALE; HUMAN; MALE; METABOLISM; VASCULAR DISEASE; VASCULAR SMOOTH MUSCLE; VEIN THROMBOSIS;

ARTERIOSCLEROSIS; BLOOD COAGULATION; ESTROGENS; FEMALE; HUMANS; LIGANDS; MALE; MUSCLE, SMOOTH, VASCULAR; RECEPTORS, ESTROGEN; REGIONAL BLOOD FLOW; VASCULAR DISEASES; VENOUS THROMBOSIS;

EID: 0035408189     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-2760(01)00406-4     Document Type: Review

References (74)

1. American Heart Association (1998) Heart and Stroke Statistical Update, American Heart Association
2. Varas-Lorenzo, C. et al. (2000) Hormone replacement therapy and incidence of acute myocardial infarction. A population-based nested case-control study Circulation 101, 2572-2578
3. Barrett-Connor, E. and Bush, T.L. (1991) Estrogen and coronary heart disease in women. J. Am. Med. Assoc. 265, 1861-1867
4. Kannel, W.B. et al. (1976) Menopause and risk of cardiovascular disease: the Framingham study. Ann. Intern. Med. 85, 447-452
5. Rossouw, J.E. (1999) Hormone replacement therapy and cardiovascular disease. Curr. Opin. Lipidology 10, 429-434
6. Varas-Lorenzo, C. et al. (1998) Hormone replacement therapy and the risk of hospitalization for venous thromboembolism: a population-based study in southern Europe. Am. J. Epidemiol. 147, 387-390
7. van Kesteren, P.J.M. et al. (1997) Mortality and morbidity in transsexual subjects treated with cross-sex hormones. Clin. Endocrinol. 47, 337-342
8. Perez Gutthann, S. et al. (1997) Hormone replacement therapy and risk of venous thromboembolism: population based case-control study Br. Med. J. 314, 796-800
9. Hulley, S. et al. (1998) Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. J. Am. Med. Assoc. 280, 605-613
10. Grady D. et al. (2000) Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The heart and estrogen/progestin replacement study Ann. Intern. Med. 132, 689-696
11. Chen, S-J. et al. (1996) Estrogen reduces myointimal proliferation after balloon injury of rat carotid artery. Circulation 93, 577-584
12. Li, G. et al. (1999) Estrogen inhibits vascular smooth muscle cell-dependent adventitial fibroblast migration in vitro. Circulation 100, 1639-1645
13. Iafrati, M.D. et al. (1997) Estrogen inhibits the vascular injury response in estrogen receptor α-deficient mice. Nat. Med. 3, 545-548
14. Karas, R.H. et al. (1999) Estrogen inhibits the vascular injury response in estrogen receptor beta-deficient female mice. Proc. Natl. Acad. Sci. U. S. A. 96, 15133-15136
15. Virchow, R.L.K. (1856) Phlogose und Thrombose im Gefäßsystem. In Gesammelte Abhandlungen zur wisenschaftlichen Medizin, Von Meidinger Sohn, Frankfurt
16. Bhagyalakshmi, A. and Frangos, J.A. (1989) Mechanism of shear-induced prostacyclin production in endothelial cells. Biochem. Biophys. Res. Commun. 158, 31-37
17. Miller, V.M. and Barber, D.A. (1996) Modulation of endothelium-derived nitric oxide in canine femoral veins. Am. J. Physiol. 271, H668-H673
18. Miller, V.M. and Michener, S.R. (1995) Modulation of contractions to and receptors for endothelins in canine veins. Am. J. Physiol. 268, H345-H350
19. Sevitt, S. (1978) Pathology and pathogenesis of deep vein thrombi. In Venous Problems (Bergan, J.J. and Yao, J.S.T., eds), pp. 257-279, Year Book Medical Publishers
20. Smith, D.F. and Toft, D.O. (1993) Steroid receptors and their associated proteins. Mol. Endocrinol. 7, 4-11
21. Kim-Schulze, S. et al. (1996) Expression of an estrogen receptor by human coronary artery and umbilical vein endothelial cells. Circulation 94, 1402-1407
22. Lindner, V. et al. (1998) Increased expression of estrogen receptor-beta mRNA in male blood vessels after vascular injury. Circ. Res. 83, 224-229
23. Losordo, D.W. et al. (1994) Variable expression of the estrogen receptor in normal and atherosclerotic coronary arteries of premenopausal women. Circulation 89, 1501-1510
24. Hodges, Y.K. et al. (2000) Estrogen receptors α and β. Prevalence of estrogen receptor β mRNA in human vascular smooth muscle and transcriptional effects. Circulation 101, 1792-1798
25. Sudhir, K. et al. (1997) Premature coronary artery disease associated with a disruptive mutation in the estrogen receptor gene in a man. Circulation 96, 3774-3777
26. Khetawat, G. et al. (2000) Human megakaryocytes and platelets contain the estrogen receptor β and androgen receptor (AR): testosterone regulates AR expression. Blood 95, 2289-2296
27. Okada, M. et al. (1997) Effects of 17 beta-estradiol and progesterone on migration of human monocytic THP-1 cells stimulated by minimally oxidized low-density lipoprotein in vitro. Cardiovasc. Res. 34, 529-535
28. Garcia-Duran, M. et al. (1999) Estrogen stimulates neuronal nitric oxide synthase protein expression in human neutrophils. Circ. Res. 85, 1020-1026
29. Bar, J. et al. (1993) The effect of estrogen replacement therapy on platelet aggregation and adenosine triphosphate release in postmenopausal women. Obstet. Gynecol. 81, 261-264
30. Ben-Hur, H. et al. (1995) Menopause is associated with a significant increase in blood monocyte number and a relative decrease in the expression of estrogen receptors in human peripheral monocytes. Am. J. Reprod. Immunol. 34, 363-369
31. Yamada, K. et al. (1996) Physiological concentration of 17 beta-estradiol inhibits chemotaxis of human monocytes in response to monocyte chemotactic protein 1. Artery 22, 24-35
32. Li, N. et al. (2000) Platelet-leukocyte cross talk in whole blood. Arterioscler. Thromb. Vase. Biol. 20, 2702-2708
33. Byrne, G.I. et al. (2000) Collaborative multidisciplinary workshop report: interface of lipid metabolism, atherosclerosis, and Chlamydia infection. J. Infect. Dis. 181, S490-S491
34. Lagrand, W.K. et al. (1999) C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon? Circulation 100, 96-102
35. Walsh, B.W. et al. (2000) The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial. J. Clin. Endocrinol. Metab. 85, 214-218
36. Torzewski, M. et al. (2000) C-reactive protein in the arterial intima. Role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler. Thromb. Vasc. Biol. 20, 2094-2099
37. Bilsel, A.S. et al (2000) Long-term effect of 17 beta-estradiol and thrombin on tissue factor pathway inhibitor release from HUVEC. Thromb. Res. 99, 173-178
38. Scarabin, P.Y. et al. (1997) Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women: a randomized controlled trial. Arterioscler. Thromb. Vasc. Biol. 17, 3071-3078
39. Walsh, B.W. et al. (1998) Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. J. Am. Med. Assoc. 279, 1445-1451
40. Kon Koh, K. et al. (1999) Relation of fibrinolytic potentiation by estrogen to coagulation pathway activation in postmenopausal women. Am. J. Cardiol. 83, 466-469
41. Cushman, M. et al. (1999) Effect of postmenopausal hormones on inflammation-sensitive proteins. The postmenopausal estrogen/progestin interventions (PEPI) study. Circulation 100, 717-722
42. Kuiper, G.G. et al. (1997) Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta Endocrinology 138, 863-870
43. Bayard, F. et al. (1995) Oestrogen synthesis, oestrogen metabolism and functional oestrogen receptors in bovine aortic endothelial cells. Ciba Found. Symp. 191, 122-132
44. Kikuchi, N. et al. (2000) Atheroprotectiveeffect of estriol and estrone sulfate on human vascular smooth muscle cells. J. Steroid Biochem. Mol. Biol. 72, 71-78
45. Dubey R.K. et al. (1999) Estrogen and tamoxifen metabolites protect smooth muscle cell membran phospholipids against peroxidation and inhibit cell growth. Circ. Res. 84, 229-239
46. Dubey, R.K. et al. (2000) Clinically used estrogen: differentially inhibit human aortic smooth muscl cell growth and mitogen-activated protein kinase activity. Arterioscler. Thromb. Vasc. Biol. 20, 964-972
47. Kalsner, S. (1969) Steroid potentiation of responses to sympathomimetic amines in aortic strips. Br. J. Pharmacol. 36, 582-593
48. Hamlet, M.A. et al. (1980) Effects of estradiol on release and disposition of norepinephrine from nerve endings. Am. J. Physiol. 239, H450-H456
49. Adlercreutz, H. (1990) Western diet and Western disease: some hormonal and biochemical mechanisms and associations. Scand. J. Clin. Lab. Invest. 210, 3-23
50. Clarkson, T.B. (2000) Soy phytoestrogens: what will be their role in postmenopausal hormone replacement therapy? Menopause 7, 71-75
51. Plouffe, L. (2000) Selective estrogen receptor modulators (SERMs) in clinical practice. J. Soc. Gynecol. Invest. 7, S38-S46
52. Agnusdei, D. and Iori, N. (1999) Tolerability profile of SERMs. J. Endocrinol. Invest. 22, 641-645
53. Figtree, G.A. et al. (2000) Tamoxifen acutely relaxes coronary arteries by an endothelium, nitric oxide, and estrogen receptor-dependent mechanism. J. Pharmacol. Exper. Ther. 295, 519-523
54. Figtree, G.A. et al. (1999) Raloxifene acutely relaxes rabbit coronary arteries in vitro by an estrogen receptor-dependent and nitric oxide-dependent mechanism. Circulation 100, 1095-1101
55. Clarkson, T.B. et al. (1998) Lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys. J. Clin. Endocrinol. Metab. 83, 721-726
56. Vogel, V.C. (2001) Chemoprevention: reducing breast cancer risk. In Management of Patients at High Risk for Breast Cancer (Vogel, V.C., ed.), Blackwell Science
57. Barrett-Connor, E. et al. (1998) Hormone and nonhormone therapy for the maintenance of postmenopausal health: the need for randomized controlled trials of estrogen and raloxifene. J. Womens Health 7, 839-847
58. Chen, Z. et al. (1999) Estrogen receptor alpha mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. J. Clin. Invest. 103, 401-406
59. Russell, K.S. et al. (2000) Estrogen stimulates heat shock protein 90 binding to endothelial nitric oxide synthase in human vascular endothelial cells. Effects on calcium sensitivity and NO release. J. Biol. Chem. 275, 5026-5030
60. 2+] efflux from female porcine coronary arterial smooth muscle. Am. J. Physiol. 45, H926-H934
61. Gratton, J.P. et al. (2000) Reconstitution of an endothelial nitric-oxide synthase (eNOS), hsp90, and caveolin-1 complex in vitro. Evidence that hsp90 facilitates calmodulin stimulated displacement of eNOS from caveolin-1. J. Biol. Chem. 275, 22268-22272
62. Shaul, P.W. (1999) Rapid activation of endothelial nitric oxide synthase by estrogen. Steroids 64, 28-34
63. Mendelsohn, M.E. (2000) Nongenomic, estrogen receptor-mediated activation of endothelial nitric oxide synthase. How does it work? What does it mean? Circ. Res. 87, 956-960
64. Russell, K.S. et al. (2000) Human vascular endothelial cells contain membrane binding site for estradiol, which mediate rapid intracellular signaling. Proc. Natl. Acad. Sci. U. S. A. 97, 5930-5935
65. Sudhir, K. et al. (1997) Endothelial dysfunction in a man with disruptive mutation in oestrogen-receptor gene. Lancet 349, 1146-1147
66. Oparil, S. et al. (1999) Estrogen attenuates the adventitial contribution to neointima formation in injured rat carotid arteries. Cardiovasc. Res. 44, 608-614
67. Parini, P. et al. (1997) Importance of estrogen receptors in hepatic LDL receptor regulation. Arterioscler. Thromb. Vasc. Biol. 17, 1800-1805
68. Begona Ruiz-Larrea, M. et al. (2000) Antioxidant activities of estrogens against aqueous and lipophilic radicals; differences between phenol and catechol estrogens. Chem. Phys. Lipids 105, 179-188
69. Daly E. et al. (1996) Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 348, 977-980
70. Jick, H. et al. (1996) Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 348, 981-983
71. New, G. et al. (1997) Long-term estrogen therapy improves vascular function in male to female transsexuals. J. Am. Coll. Cardiol. 29, 1437-1444
72. Komori, K. et al. (1989) Endothelium-dependent relaxation in response to aggregating platelets in porcine femoral veins and its modulation by diet. Circulation 80, 401-409
73. Barber, D. and Miller, V. (1998) Endothelium-dependent vasoconstrictors. In Endothelial Cell Research (Rubanyi, G., ed.), pp. 167-185, Harwood Academic Publishers
74. Psaty B.M. et al. (2001) Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal myocardial infarction in postmenopausal women. J. Am. Med. Assoc. 285, 906-913